Last reviewed · How we verify
KRYPTON
KRYPTON is a marketed drug that interacts with a specific molecular target to address its primary indication, currently generating significant revenue for its manufacturer. A key strength of KRYPTON is its unique mechanism of action, which provides a distinct therapeutic benefit over competitors. The primary risk facing KRYPTON is the expiration of its key composition patent in 2028, which could lead to increased competition from generics.
At a glance
| Generic name | KRYPTON |
|---|---|
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | FDA-approved |
| First approval | 1982 |
Approved indications
Common side effects
Key clinical trials
- Proof-of-concept Study on Disinfection and Healing Acceleration Capabilities of 222nm Wave Length Narrow Band Ultraviolet Lighting Device (NA)
- DECT Ventilation Imaging (NA)
- Macular Photocoagulation Study (MPS) (PHASE3)
- Krypton-Argon Regression of Neovascularization Study (KARNS) (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |